Auxilium Pharmaceuticals Receives Consensus Recommendation of “Hold” from Analysts (NASDAQ:AUXL)
Auxilium Pharmaceuticals (NASDAQ:AUXL) has earned a consensus recommendation of “Hold” from the sixteen ratings firms that are currently covering the stock, StockRatingsNetwork.com reports. Four analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $26.79.
Auxilium Pharmaceuticals (NASDAQ:AUXL) traded down 0.60% during mid-day trading on Friday, hitting $21.58. The stock had a trading volume of 103,618 shares. Auxilium Pharmaceuticals has a 52-week low of $14.74 and a 52-week high of $32.89. The stock has a 50-day moving average of $23.79 and a 200-day moving average of $23.86. The company’s market cap is $1.084 billion.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.22. The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $89.20 million. During the same quarter last year, the company posted ($0.05) earnings per share. Auxilium Pharmaceuticals’s revenue was up 33.7% compared to the same quarter last year. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.18 earnings per share for the current fiscal year.
AUXL has been the subject of a number of recent research reports. Analysts at TheStreet downgraded shares of Auxilium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note on Thursday. They now have a $33.00 price target on the stock, down previously from $34.00. Finally, analysts at Zacks downgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $18.00 price target on the stock.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.